Update: NCCN breast cancer clinical practice guidelines

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 3, Issue SUPPL. 1, 2005, Pages

  Carlson, Robert W ^a   McCormick, Beryl ^b  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Breast cancer; Hormonal therapy; NCCN Clinical Practice Guidelines; Radiation therapy

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; EXEMESTANE; LETROZOLE; PLACEBO; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADJUVANT CHEMOTHERAPY; BRACHYTHERAPY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; HORMONAL THERAPY; HUMAN; MASTECTOMY; MEDICAL SOCIETY; MENOPAUSE; MICROMETASTASIS; MULTIMODALITY CANCER THERAPY; PARTIAL MASTECTOMY; PRACTICE GUIDELINE; SALVAGE THERAPY; TREATMENT INDICATION; ADJUVANT THERAPY; AGE; AGED; ARTICLE; BREAST TUMOR; FEMALE; MIDDLE AGED; UNITED STATES;

AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MENOPAUSE; MIDDLE AGED; PRACTICE GUIDELINES; RADIOTHERAPY, ADJUVANT; UNITED STATES;

EID: 33644845339     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (10)

1. Hughes KS, Schnaper LA, Berry D et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med 2004;351:971-977.
2. Fyles AW, McCready DR, Manchul LA, et al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med 2004; 351:963-970.
3. Ragaz J, Jackson SM, Le N, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 1997;337:956-962.
4. Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high risk women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997; 337:949-955.
5. Woodward WA, Strom EA, Tucker SL, et al. Locoregional recurrence after doxorubicin-based chemotherapy and postmastectomy: implications for breast cancer patients with early-stage disease and predictors for recurrence after postmastectomy radiation. Int J Radiat Oncol Biol Phys 2003;57:336-344.
6. Vicini F, Baglan K, Kertin L, et al. Accelerated treatment of breast cancer. J Clin Oncol 2001;19:1993-2001.
7. Baum M, Buzdar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of post menopausal women with early stage breast cancer: results of the ATAC trial efficacy and safety update analyses. Cancer 2003;98:1802-1810.
8. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003:349:1793-1802.
9. Goss PE, Ingle JN, Martino S, et al. Updated analysis of the NCIC CTG MA.17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women with early stage breast cancer. J Clin Oncol 2004;22(Suppl):847.
10. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;351:1081-1092.